ArticleAntioxidants (Basel, Switzerland)2026
Perspective: Beta Cell Glucose Toxicity in Type 2 Diabetes: Nrf2 and the Endogenous Antioxidant Response.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing attention is being given to the concept that mild hyperglycemia in patients with early type 2 diabetes initiates a vicious cycle in which progressively higher levels of glycemia generate higher levels of reactive oxygen species (ROS) both in the general blood circulation and within the beta cells themselves. Theoretically, over time, this might worsen already damaged beta cell function (glucose toxicity) and augment progression to frank hyperglycemia. At issue is whether in the early stages of type 2 diabetes the beta cell is simply a passive victim in this scenario or whether it might try to mount an endogenous antioxidant response to defend itself against local excessive ROS formation. Since Nrf2 is the primary regulator of endogenous antioxidant synthesis, a greater understanding of Nrf2 activity in beta cells undergoing hyperglycemic stress may lead to new therapeutic insights for type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.